GNI Group (TYO:2160) said its core subsidiary, Gyre Therapeutics, completed a public offering of common stock, raising about $23 million in gross proceeds, according to a Monday filing on the Tokyo Stock Exchange.
The offering closed on May 29, with Gyre issuing 2,555,555 shares at $9 apiece, including 333,333 shares from the underwriters' overallotment option, the filing said.
GNI said its ownership in Gyre has decreased to 80.69% from 83.03%, though the unit remains a consolidated subsidiary of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.